Transplantation Biology Research Center, Massachusetts General Hospital, Building 149, 13th Street, Boston, MA 02129, United States.
Semin Immunol. 2011 Jun;23(3):165-73. doi: 10.1016/j.smim.2011.07.001. Epub 2011 Aug 11.
The induction of transplantation tolerance could liberate organ transplant recipients from the complications of life-long chronic immunosuppression. The original description of tolerance induction through mixed hematopoietic chimerism in mice utilized lethal whole body irradiation as the preparative regimen for achieving mixed chimerism. While such a regimen might be acceptable for treatment of patients with malignancies, which might also respond to the therapeutic effects of radiation, its toxicity would be unacceptable for patients in need only of an organ transplant. Graft-vs.-host disease, which is frequently a complication of mismatched bone marrow transplantation, would likewise be unacceptable for ordinary clinical transplantation. Therefore, as we have extended the use of this modality for tolerance induction from mice to large animal models, we have attempted to design preparative regimens that avoid both of these complications. In this article, we review our studies of mixed chimerism in mice, miniature swine and monkeys, as well as the results of our recent clinical studies that have extended this treatment modality to a series of kidney transplant patients who have been successfully weaned from all immunosuppression while maintaining stable renal function for up to 8 years.
诱导移植耐受可以使器官移植受者摆脱长期慢性免疫抑制的并发症。最初在小鼠中通过混合造血嵌合诱导耐受的描述使用致死性全身照射作为实现混合嵌合的预备方案。虽然这种方案对于治疗可能对放射治疗有反应的恶性肿瘤患者可能是可以接受的,但对于仅需要器官移植的患者来说,其毒性是不可接受的。移植物抗宿主病是骨髓移植不匹配的常见并发症,对于普通临床移植来说也是不可接受的。因此,当我们将这种诱导耐受的方式从小鼠扩展到大动物模型时,我们试图设计避免这两种并发症的预备方案。在本文中,我们回顾了我们在小鼠、小型猪和猴子中进行的混合嵌合研究,以及我们最近的临床研究结果,这些研究将这种治疗方式扩展到一系列已成功摆脱所有免疫抑制的肾移植患者,并且肾功能稳定长达 8 年。